# A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals.

> **NCT04882514** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 30 (actual)

## Conditions studied

- Group A Streptococcal Infection

## Interventions

- **BIOLOGICAL:** p*17-K4S2
- **BIOLOGICAL:** J8-K4S2
- **BIOLOGICAL:** Rabavert vaccine

## Key facts

- **NCT ID:** NCT04882514
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882514, "A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04882514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*